Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 185Neoplasms 178Carcinoma, Non-Small-Cell Lung 162Prostatic Neoplasms 114Colorectal Neoplasms 111Lung Neoplasms 94Ovarian Neoplasms 85Neoplasm Metastasis 80Multiple Myeloma 75Pancreatic Neoplasms 73Leukemia, Myeloid, Acute 68Endometrial Neoplasms 53Stomach Neoplasms 49Squamous Cell Carcinoma of Head and Neck 48Melanoma 48Lymphoma 46Glioblastoma 45Recurrence 44Carcinoma, Renal Cell 44Urinary Bladder Neoplasms 42Carcinoma, Hepatocellular 41Brain Neoplasms 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Sarcoma 38Lymphoma, Non-Hodgkin 36Leukemia, Lymphocytic, Chronic, B-Cell 36Glioma 36Hematologic Neoplasms 35Small Cell Lung Carcinoma 34Esophageal Neoplasms 33

Interventions

Palonosetron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Nausea × 30 days × Clear all
NCT07169851 2026-06-04

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Eli Lilly and Company

Phase 2 Recruiting
204 enrolled

Nausea, Neoplasms, Vomiting, Drug-Related Side Effects and Adverse Reactions

NCT06904235 2026-06-01

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

Helsinn Healthcare SA

Phase 2 Recruiting
95 enrolled

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡